Washington State Life Science Investment Report
June 2021

A monthly report summarizing life science transactions in Washington State.

BY THE NUMBERS: (YTD) 62 TRANSACTIONS TOTALING OVER $3.76B

Deals Per Sector



Disclosed Funding By Sector



JUNE TOP TRANSACTIONS

Nautilus Biotechnology, a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the completion of its business combination with Arya Sciences Acquisition Corp III. Gross proceeds from this transaction to Nautilus totaled approximately $345M (BioSpace).

Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies, announced the completion of an oversubscribed $210M Series B financing (Umoja Biopharma).

Kineta, a Seattle-based clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, closed its $10M financing round. Proceeds from this financing will advance the company's lead anti VISTA antibody, KVA12.1 to an IND with the U.S. FDA in 2022 (Finsmes).

OTHER TRENDS & HIGHLIGHTS

Isoray, the Richland company that makes radioactive seeds to treat prostate cancer, has raised more than $50M through supplemental stock offerings in recent months, with most targeted to expand its reach to other types of cancer (Tri Cities Journal of Business).

Lightspeed Microscopy, an end-to-end 3D pathology platform, announced it has raised $4M in a Series A financing round. The round was led by Dynamk Capital and is expected to close with participation from additional investors by mid-July (BioSpace).

AbSci has raised $100M in the third Washington-state biotech IPO of 2021 (following Sana Biotech in February and Impel NeuroPharma in April). Absci, based in Vancouver, partners with other biopharma companies to identify and develop protein-based drug candidates (GeekWire).

TRANSACTIONS

Date	Company	Sector	Type	Amount	Location
01-Jun-2021	RimBio	Medtech	Merger/ Acquisition	undisclosed	Seattle
02-Jun-2021	Kineta	Biotech	Later Stage VC	$10,000,000	Seattle
08-Jun-2021	Mytaptrack	Digital Health	Equity Crowdfunding	$30,000	Enumclaw
09-Jun-2021	Nautilus Biotechnology	Biotech	Reverse Merger/ PIPE	$345,000,000	Seattle
15-Jun-2021	Nortis	Biotech	Later Stage VC	$2,500,000	Woodinville
15-Jun-2021	Umoja Biopharma	Biotech	Early Stage VC	$210,000,000	Seattle
22-Jun-2021	Lightspeed Microscopy	Medtech	Early Stage VC	$4,580,000	Redmond
30-Jun-2021	AbSci	Biotech	IPO	$100,000,000	Vancouver

June Total (disclosed transactions): $672,110,000
May Total (disclosed transactions): $14,530,000
April Total (disclosed transactions): $841,190,000
March Total (disclosed transactions): $1,089,960,000
February Total (disclosed transactions): $666,580,000
January Total (disclosed transactions): $478,070,000

This report is prepared by Aylin Kim, Manager of Entrepreneurship at LSW Institute. Questions or comments? Contact aylin@lswinstitute.org. *The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information as of July 4, 2021 at 1:56 pm. It is not independently verified by Life Science Washington Institute. Grants are not reported in this summary.